Jaishri Blakeley, MD

Johns Hopkins University

Dr. Jaishri Blakeley is a clinician scientist with research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors and incorporation of patient focused, functional endpoints into efficacy studies. She has been the national or international leader of seven clinical trials focused on therapies for glioblastoma, Neurofibromatosis Type 2 (NF2) and Neurofibromatosis Type 1 (NF1). In 2012 she cofounded the Neurofibromatosis Therapeutic Acceleration Program (NTAP) to dramatically shift the landscape of NF1 clinical care via necessary, efficient and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 50 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1 associated neoplasms. The results have been a transformation of the research landscape for both plexiform and cutaneous neurofibromas, including contribution to the development of MEKi inhibitors for these tumors. In addition, NTAP has facilitated a culture of team science that supports all stakeholders in the research process and maximizes the value of each investigation and contributor. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis and primary brain cancer for whom she is honored to provide care.


NOTE: If no session is listed above, this individual is a Chair or Co-chair of a session(s). Please see the individual session listings found in the Program for a full list of session participants.